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ABSTRACT:
Background: The risk of psychosocial harm in families of infants with false positive (FP)
newborn screening (NBS) results for cystic fibrosis (CF) is a longstanding concern. Whether
well designed infant retrieval and confirmatory testing systems can mitigate risks remains
unknown.
Methods: Using a mixed-methods cohort design, we obtained prospective self-report data from
mothers of infants with FP CF NBS results 2-3 months after confirmatory testing at Ontario’s
largest follow-up centre, and from a randomly selected control sample of mothers of screen
negative infants from the same region. Mothers completed a questionnaire assessing experience
and psychosocial response. A sample of mothers of FP infants completed qualitative interviews.
Results: 134 mothers of FP infants (Response Rate 55%) and 411 controls (Response Rate
47%) completed questionnaires; 54 mothers of FP infants were interviewed. Selected
psychosocial response measures did not detect psychosocial distress in newborns or one year
later (p > 0.05). Mothers recalled distress during notification of the positive result and in the
follow-up testing period related to fear of chronic illness, but valued the screening system of
care in mitigating concerns.
Conclusions: While immediate distress was reported among mothers of FP infants, selected
psychometric tools did not detect these concerns. The NBS centre from which mothers were
recruited minimizes delay between notification and confirmatory testing and ensures trained
professionals are communicating results and facilitating follow-up. These factors may explain
the presence of minimal psychosocial burden. The screening system reflected herein may be a
model for NBS programs working to minimize FP-related psychosocial harm.
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Introduction
Newborn bloodspot screening (NBS) for cystic fibrosis (CF) is now established in many
developed countries,1-4 as early detection improves nutritional status, height and weight gain.5
CF is the largest single disease contributor to screen positive NBS results in many jurisdictions,
and is an exemplar case for understanding the impact of expanded NBS. Approximately 30% of
screen positive cases/year identified in Ontario are attributable to CF,6 the majority of which are
false positive (FP) upon confirmatory testing; as many as 80% of these are CF carriers.6,7

As part of efforts to balance benefits and burdens of population screening, the impact of FP
results has long garnered attention. In the context of NBS, the concern dates back to 1968 when
“PKU-Anxiety Syndrome” described the distressing experience of receiving FP results for
phenylketonuria (PKU).8 Evidence has since accumulated suggesting that parents may
experience a range of reactions related to receiving positive CF NBS results. Tluczek et al9
found that prior to confirmatory CF sweat testing, up to 43% of parents who had received an
abnormal screening result experienced clinically significant depressive symptoms. However,
after the sweat test, parents whose infants were found to be CF carriers did not differ from
screen negative controls. Parents’ prior knowledge of NBS, CF, and their own carrier status as
well as the clinician’s approach to informing them influenced this emotional reaction.9
Similarly, others have found that majorities of parents (74-96%) reported high anxiety in
reaction to positive NBS results but upon receiving normal sweat test results, majorities (64–
86%) were relieved.10,11 While detected anxiety appears to be transient,9-11 one to six years after
identification, up to 29% of parents report worry about the health of their carrier child as well as
potential difficulties posed for future relationships. Stress scores are also higher at one year
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post-disclosure among parents who received CF carrier versus negative results .12-13 Parsons et
al,14 however, found that by 6 months post-disclosure, there was no evidence that carrier
identification was associated with a compromised mother–baby relationship. Other survey and
qualitative data suggest that, ultimately, the majority of parents feel better knowing their child’s
CF carrier status. 9,15

While the negative psychosocial impact of FP results appears to be transient, vulnerability
remains a concern. Responding to this evidence and as a broader measure of quality, Newborn
Screening Ontario developed programmatic recommendations to minimize delay to
confirmatory testing, ensure trained health professionals are communicating results to parents,
and build partnerships with primary care providers. Presented herein are quantitative and
qualitative data that reflect upon maternal lived experiences soon after CF NBS FP result
notification in the context of a centralized provincial program.

Participants and Methods
In Ontario, CF NBS involves a two-step process of measuring immunoreactive trypsinogen
(IRT) followed by screening the CF transmembrane regulator gene for 39 mutations.6 Infants
with identified to have one CF mutation or an IRT > 99th centile are referred for diagnostic
sweat chloride testing. In collaboration with the CF clinic at the Hospital for Sick Children
(SickKids) in Toronto (largest pediatric tertiary care centre in Canada), we conducted selfadministered postal surveys of mothers of CF screen positive infants and a control sample, at 2
months following the infant’s birth (T1) and one year later (T2). We also conducted semistructured interviews with a sub-sample of FP survey respondents at both time-points. While
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the complete screen positive population included true-, false-, and inconclusive- positive
infants, we focus herein on the longitudinal results from the T1 FP responder group. Research
Ethics Boards at SickKids, The Children’s Hospital of Eastern Ontario, and The University of
Toronto approved this work.

Sample and Recruitment
T1 recruitment of mothers was prospective over 18 months. The full population of mothers of
CF screen positive infants seen at SickKids, aged 4-6 weeks (i.e. confirmatory testing
complete), were eligible to participate. Those facing extenuating perinatal circumstances, those
undergoing adoption proceedings, mothers of multiples, and mothers facing a significant
language barrier were excluded. The control sample (3:1 control:case ratio) included a random
sample of mothers of infants in the population who screened negative for all disorders included
in Ontario’s NBS panel, resided within the SickKids catchment area (i.e. according to postal
code boundaries), and were 4-6 weeks old. Mothers of infants with an unsatisfactory bloodspot
were excluded as were mothers of infants facing adoption proceedings, blood transfusion,
prematurity (i.e. gestational age <36 weeks), early death, or > 60 day delay between date of
birth and date of bloodspot collection.

Mothers of FP infants were notified of the study verbally and with a letter of introduction at the
conclusion of their confirmatory sweat-testing appointment (4-6 weeks post-birth). Four weeks
following this notification, potential participants who had not opted out were mailed a survey
package. One follow-up package was sent one month later. For screen negative controls,
mothers were notified of the study by mail, 4 weeks following birth. Potential controls who had
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not opted out were mailed a survey package and invited to participate, with three additional
contacts (at 2-week intervals) for non-responders (i.e. modified Dillman method).15 In response
to a poorer than expected response rate at three months (presumed attributable to the young age
of the baby at initial contact), the recruitment timelines were slightly extended (Box 1). The
overall shorter recruitment timeline for FP cases compared to controls reflects the differential
burden appropriate to clinical and non-clinical study populations.16,17 Completion of the
questionnaire constituted consent to participate. At T2, one year following the completion or
administration of the T1 survey, T1 responders and non-responders were mailed a slightly
modified second survey. The recruitment and survey administration process was the same as
that used at T1 with FP notification mail.

Data Collection and Analysis: Survey
The survey package included (i) a team-developed, self-administered questionnaire gauging CF
knowledge, understanding of screening result, experiences with the notification process, (ii) 5
self-administered measures of psychosocial response, (iii) demographic questions, and (iv) a
study information sheet, a consent to re-contact form for the qualitative interview, and a small
financial incentive ($2 coffee coupon). The questionnaire was adapted from existing
instruments developed for NBS and CF research9-15, 21-22, 28-48 and pilot tested with new parents
recruited from the Greater Toronto Area (N=15) through an online mothers’ group. The core
of the questionnaire was consistent across FP and control groups; non-applicable FP related
content was removed from the control group questionnaire. The measures of psychological
response included: (i) the State Subscale of the State Trait Anxiety Inventory (STAI) as a
measure of anxiety,28-32 (ii) the Brief Symptom Inventory (BSI) as a measure of distress,33-39
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(iii) the Child Vulnerability Scale (CVS) as a measure of maternal perception of infant
vulnerability,40-43 (iv) a modified version of the Parental Perceptions of Uncertainty in Illness
Scale (PPUS) as a measure of perceived uncertainty related to childhood illness,44-47 and (v) a
modified version of the Maternal Worry Scale (MWS) as a measure of maternal worry48 (Box
2).

Questionnaire data were manually entered into IBM SPSS Statistics version 18. Where the data
entry error rate was >0.50%, full double data entry was performed. We report cross-sectional
analyses for T1 and repeated measures analyses for the subsample of respondents who
completed both T1 and T2 questionnaires. We quantified the overall pattern of responses,
reporting proportions with 95% CIs for discrete variables and means with standard deviations
for continuous variables, for each of the FP and screen negative groups. T-tests were performed
on log-transformed STAI, CVS, and PPUS scale data and on BSI t-scores. Since MWS scores
were highly skewed and did not respond favorably to power transformation, non-parametric
tests were used to gauge group differences. For T1 data, linear regression was performed to
examine the association of FP status with anxiety, distress, vulnerability, and uncertainty,
controlling for maternal characteristics where there was a difference between groups. Given
multiple comparisons in the regression models, a more stringent p value (p<0.01) was used to
determine statistical significance. We then performed two-factor mixed ANOVAs to gauge the
effect of time on anxiety, distress, vulnerability, and uncertainty. Maternal worry was analyzed
separately because data were concentrated at a score of 10. We subtracted 10 from each score
and treated the data as count data in order to compare screen negative and FP groups at each
time point. Negative binomial regression was used for the subsample for whom we had T1 and
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T2 worry data (total n=255), adjusting for the same confounders as the T1 linear regressions. At
T2, a repeated measures negative binomial regression was performed on worry data.

Data Collection and Analysis: Interviews
Following our receipt of completed questionnaires, we conducted semi-structured, open-ended
interviews with all mothers of FP infants who agreed (by checking a box on the questionnaire).
Interviews were conducted by telephone where face-to-face was not preferred, or because of
excess cost of travel to a distant location. The interview guide queried mothers’ experiences
receiving results, and their understanding of screen positive and confirmatory sweat testing
results. Interviews were taped, transcribed and coded. We used a thematic approach, applying
and modifying pre-existing codes from the interview guide pertaining to the experience of
receiving FP results, and allowed new themes to emerge from the data using constant
comparison. Through an iterative process, codes were refined and inconsistencies were resolved
through discussion.49,50 We used T1 interviews to identify themes and then searched for
confirming/disconfirming evidence and persistence of experience in T2 interviews.

Results
Quantitative findings
Characteristics of survey respondents
Of 246 eligible mothers of infants who received FP NBS results, 134 responded (RR=54.5%) to
the survey, and of 869 eligible mothers of screen negative infants, 410 responded (RR=47.2%).
Among mothers of FP infants, we report on 134 mothers (T1) of whom 82 (T2) completed T1
and T2 surveys. According to mothers, 141 (65.2%) of these infants were confirmed to be
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carriers, 44 (20.4%) were confirmed non-carriers, and for 31 (14.4%), carrier status was
unknown. Among screen negative infants, we report on 410 mothers (T1) of whom 179 (T2)
completed T1 and T2 surveys.

The characteristics of our survey samples are reported in Table 1. At T1, compared to controls,
a greater proportion of mothers of FP infants reported living in rural areas (p<0.05), fewer had
completed undergraduate (or higher) degrees (p=0.02) and more reported that the index infant
was their first child (p=0.01). Compared to an Ontario-based CF population, our participants
were similar in education and income levels.51
Psychosocial outcomes
In both the FP and control groups at T1 and T2, mean anxiety, distress, and vulnerability scores
were low relative to reference means or clinical cut-offs where these were available from the
literature (Box 2, Table 2), and not significantly different between groups (Table 2). While
uncertainty scores were significantly different between groups at T1, the control group reported
more uncertainty than the cases (p=0.03; Table 2). Results of linear regression showed that FP
status did not predict anxiety, distress, vulnerability or uncertainty at T1, controlling for
relevant maternal characteristics (Table 3). Repeated measures analyses indicated no change in
psychosocial response over time, except that uncertainty scores remained higher among
controls at T2 (p=0.03; data not shown).

Maternal worry scores were significantly higher among mothers of FP infants compared to
controls at T1 and T2 (p=0.002, p=0.004; Table 2). When the worry scale item related to carrier
children having a harder time making reproductive choices was removed (worry_revised), the
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significance of this effect disappeared. Adjusting for maternal characteristics, the negative
binomial regression at T1 (using the 10-item worry scale) showed that FP status did not predict
worry. Over time, worry decreased (p=0.01), and there was no difference between FP and
controls on T2 worry scores (data not shown).

Self-reported experiences
With respect to the notification system itself, 61% of mothers in the FP group were notified of
their results from their primary care provider and 39% were notified by a genetic counselor.
Only 13% indicated that they would have preferred to receive this notification from someone
else; of those 47% indicated a preference for their primary care provider and 53% indicated a
preference for a counselor from the screening program. Finally, when prompted by a survey
question, 87% of mothers agreed that the time between being notified about the positive screen
and learning the final results “was the scariest time of my life.” At the time of the second
survey, only 14% agreed with this fear.

Qualitative findings
Characteristics of interview participants
31 mothers who received FP results for their infants were interviewed at T1 and 35 mothers
were interviewed one year later, at T2. Of those interviewed at T2, 23 were new participants
and 12 were interviewed at T1 and comprise a longitudinal sub-sample.

The lived experience
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From 31 T1 qualitative interviews, we identified two major themes. The first relates to the
nature of the distress that was experienced. From mothers’ perspectives, receiving the
notification phone call was frightening. Having been home from hospital with an apparently
healthy baby and having perceived their discharge and non-involvement with the health care
system as a “clean bill of health,” it was alarming to learn that their child might have a chronic
illness. Mothers reasoned that receiving this news on the heels of their own post-partum
recovery likely added to the intensity of their response. Following receipt of this unexpected
information, mothers attributed unusual newborn behavior (e.g. congestion, spit up, raspy
breathing) to a possible diagnosis of CF, described a process of symptom seeking (e.g. licking
the baby to gauge “saltiness”), and a fear of living a life with a child with a chronic illness
(Table 4). Among 23 new participants interviewed at T2, most reported similar distress in
retrospect, but few reported ongoing distress. Of the 12 longitudinal participants, 3 reported a
persistence of the distress that was reported at T1.

The second major theme relates to how the screening and tertiary care systems – and various
players within this coordinated system – were valued by mothers and worked to mitigate the
distress that was experienced. Mothers placed tremendous value on the fact that time to
confirmatory testing was quick (generally <48 hours). They valued the active coordination of
their care; specifically, being given a time and location to attend for confirmatory testing.
While mothers had mixed views about the importance of pre-test NBS education, mothers
valued what they experienced as clear, calm, and sensitive communication from the involved
heath care providers at both notification and confirmatory points in time (Table 4).
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Discussion
Using mixed methods, we provide a unique contribution to unresolved questions of
psychosocial response to FP NBS results. A first key finding is that measures of psychosocial
harm related to anxiety, distress, vulnerability and uncertainty were not increased in mothers of
infants with FP results in the early newborn period or one year later. While no signal of harm
was detected on these psychometric tools, a majority of mothers agreed that the FP experience
had been the “scariest time in their lives” and reported worry about future family planning for
their carrier infants. Similarly, in interviews, mothers of infants with FP results recalled distress
during the notification and diagnostic follow-up periods, stemming from the unexpected nature
of the information, symptom-seeking, and a fear of chronic disease. For most, distress did not
persist one year later.

Our second key finding relates to the NBS system itself. Given longstanding concern about the
risk of psychosocial harm in families of infants with FP results, NBS programs seek to mitigate
potential distress.52-58 Specifically, Ontario has developed a notification system that aims to
minimize delay to confirmatory testing, provides point of care fact sheets to health
professionals who are communicating results to parents and responding to questions, and aims
to achieve a partnership with primary care providers who often play an initial notification role.
Our qualitative data indicate that parents valued this carefully structured screening system and
perceive its role in mitigating FP-related distress. More specifically, parents valued the short
waiting period preceding confirmatory testing. While measurable psychosocial distress has
been identified among parents of screen positive infants, this may be associated with the longer
waiting periods for confirmatory testing that were experienced in earlier years of CF NBS.9,59-61
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The absence of such distress on similar tools used herein underscores the importance of short
waiting periods (i.e. <48 hours) for optimal patient experience. Additionally, mothers were
content to defer to the screening system for logistics pertaining to follow-up and reflected
favorably on provider communication and education strategies, whether offered by primary care
providers or NBS program-affiliated genetic counselors.

We acknowledge several limitations. Since our study attracted a well-educated cohort of
mothers that may have been better equipped to understand this experience, our findings may not
be generalizable to mothers with less education. Others have reported an important link
between knowledge/understanding of NBS results and psychosocial response9,15 so our findings
must be considered in this light. Moreover, mothers of FP infants who are confirmed to be
carriers may respond favorably to the receipt of this reproductive risk information.10 The
majority of our cohort represents the experience of mothers of carrier infants, possibly limiting
the generalizability of these results to mothers of FP non-carriers. Second, our qualitative
interviews were designed as two cross-sectional interviews, so did not actively probe change
over time. Finally, the results may not be applicable to other disease screen positive
populations.

Limitations notwithstanding, our mixed methods approach enables an enhanced understanding
of maternal response to FP NBS results. While our findings from selected psychometric tools
align with previous studies that report minimal adverse psychosocial sequelae,9-11 other survey
and qualitative findings suggest that parents experience distress and depend on the support
provided by a well-structured screening system. Parental reflections on the role of the screening
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system in mitigating potential distress are novel and confirm the need for investment in
centralized, well-coordinated, efficient screening systems in all jurisdictions to optimize patient
experiences and outcomes.

Acknowledgement: We thank Dr. Rahim Moineddin for his support with statistical analyses.
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Box 1: Time 1 Recruitment
Wks post birth
Cases
Controls

4-6

X
X

6-8

8-10

10-12

12-14

14-16

14-16

16-18

X

X
X

X
X

X
X

X
X

X

X

X: original recruitment schedule X: extended recruitment schedule

Box 2: Psychosocial Response Tools
Scale
STAI (20
item)28

Item Format
4-point scale from ‘not at
all’ to ‘very much so’

BSI (53
items)33

5-point scale from ‘not at
all’ to ‘extremely’

CVS (8items)40

4-point scale from
‘strongly disagree’ to
‘strongly agree’

PPUS (4
items)44

5-point scale from
‘strongly agree’ to
‘strongly disagree’

MWS (10item)48

4-point scale; worry ‘
most of the time’,
‘often’, ‘sometimes’, and
‘not at all’

Psychometric Properties
Scores range from 20-80; mean (working
women) is 34.79 (SD=9.22); mean (14w
postpartum women) 30.43; good construct
validity, discriminating adults with
generalized anxiety disorder28
Internal consistency, test-retest reliability
and validity demonstrated33

Total scores range from 0–24. In a clinical
population, scores ≥ 10 indicate elevated
perceptions of vulnerability; Internal
consistency, test-retest reliability and
validity are well demonstrated 40
Measures the uncertainty parents
experience related to their child's illness;
higher scores indicate greater perception of
uncertainty. Internal consistency, testretest reliability and validity
demonstrated44; modified as per Table 3
Internal consistency, test-retest reliability
and validity demonstrated48; modified as
per Table 3

Domains of use
Used in NBS research to
measure anxiety14,29-32

Used to assess impact of
newborn diagnosis and as
a measure of adjustment
over time.34-39 Has not
been used in NBS research
Used in NBS research to
measure response to
positive NBS results41-43
Used to gauge perceived
parental uncertainty
between identification of
symptoms in a child and
point of diagnosis.45-47 Has
not been used in NBS
research
Used for mothers of
children with chronic
illness.48 Hasnot been used
in NBS research
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Table 1: Overall Sample Characteristics
Time 1

Age
25 and under
26-30
31-35
36+
City of residence, population size
100,000 +
< 100,000
First childa
Yes
No
Marital status
Married or common law
Other
Education, highest level completed
High school or less
College or CEGEP
Undergrad
Grad or professional
Annual household income
Under $80,000
$80,000 +
p-value < 0.05 ^ Fisher’s Exact

False
positive
(n, %)

Screen
negative
(n, %)

n=134
9 (6.7%)
28 (20.9%)
59 (44.0%)
38 (28.4%)
n=133
93 (69.9%)
40 (30.1%)
n=134
72 (53.7%)
62 (46.3%)
n=134
123 (91.8%)
11 (8.2%)
n=134
18 (13.4%)
54 (40.3%)
27 (20.1%)
35 (26.1%)
n=129
52 (40.3%)
77 (59.7%)

n=405
26 (6.4%)
110 (27.2%)
160 (39.5%)
109 (26.9%)
n=410
330 (80.5%)
80 (19.5%)
n=315
127 (40.3%)
188 (59.7%)
n=410
380 (92.7%)
30 (7.3%)
n=408
57 (14.0%)
107 (26.2%)
112 (27.5%)
132 (32.4%)
n=398
180 (45.2%)
218 (54.8%)

Time 2
X2
p-value

0.54

0.02*

0.01*

0.71

0.02*

0.36

False
positive (n,
%)

Screen
negative (n,
%)

n=82
3 (3.7%)
14 (17.1%)
33 (40.2%)
32 (39.0%)
n=81
54 (66.7%)
27 (33.3%)
n=82
46 (56.1%)
36 (43.9%)
n=82
79 (96.3%)
3 (3.7%)
n=82
9 (11.0%)
29 (35.4%)
20 (24.4%)
24 (29.3%)
n=78
22 (28.2%)
56 (71.8%)

n=179
3 (1.7%)
36 (20.1%)
72 (40.2%)
68 (38.0%)
n=179
141 (78.8%)
38 (21.2%)
n=179
82 (45.8%)
97 (54.2%)
n=179
166 (92.7%)
13 (7.3%)
n=179
23 (12.8%)
42 (23.5%)
55 (30.7%)
59 (33.0%)
n=163
58 (35.6%)
105 (64.4%)

X2
p-value

0.73^

0.045*

0.14

0.29

0.25

0.26
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Table 2: T1 cross sectional & T2 longitudinal maternal psychosocial response
Time 1~

Time 2~

Mean scores (SD)

Mean scores (SD)

False positive

Screen
negative

t-test p-value

False positive

Screen
negative

t-test p-value

Anxiety

31.23 (10.30)

32.39 (8.94)

0.12

31.48 (9.03)

32.74 (10.23)

0.41

Distress^

55.35 (9.90)

56.03 (10.67)

0.52

53.85 (10.46)

53.79 (11.21)

0.97

Vulnerability

4.79 (3.49)

5.53 (4.16)

0.26

4.59 (3.60)

5.23 (3.68)

0.22

Uncertainty^^

8.04 (2.41)

8.61 (2.64)

0.03*

7.57 (2.37)

8.19 (2.50)

0.051

Worry^^^

10.81 (2.51)

10.71 (2.27)

.002**

10.73 (2.30)

10.39 (1.40)

.004**

Worry_revised

9.49 (2.42)

9.66 (2.08)

.314

9.46 (2.27)

9.36 (1.26)

.41

*p < .05; ** p < .019; : t-tests performed on log transformed scale data, descriptive statistics reported on raw data; ~T1
participants completed survey when infants was 2 months of age; T2 survey completed 1 year later; ^BSI: t scores reported;
measured 15 items to gauge general distress, using the depression and obsessive behaviors sub-scales and l 4 additional items to
generate Global Severity Index33,37-39 ^^PPUS: eliminated items related to medical treatment, attitudes toward health care
providers, and items not specifically about uncertainty in health and illness; revised items to be about babies and to be CFspecific ^^^MWS: changed “health condition” to “health”, removed 4 items specific to being sick/using medication, added 3
items to suit context of genetics; Mann-Whitney U test performed due to the nonparametric nature of data; MWS means
reported for consistency with other measures; MWS_revised: 9-item version with the item re: worry about children’s choices
about having children removed.

Table 3. Psychosocial response regression results at Time 1
Anxiety
Distress

Vulnerability

Uncertainty

(B, SE)

(B, SE)

(B, SE)

(B, SE)

FP (ref: control)

-.013 (.013)

-.405 (1.129)

-.024 (.036)

-.033a (.014)

First child missing (ref:
no)

.023 (.015)

.954 (1.308)

.005 (.041)

.013 (.017)

First child – yes (ref: no)

-.012 (.012)

.093 (1.026)

-.035 (.033)

.023 (.013)

City size – 100,000+ (ref:
<100,000)

.000 (.013)

.435 (1.129)

.012 (.036)

-.010 (.014)

Education:
college/CEGEP (ref:
grad/professional)

.012 (.014)

1.213 (1.194)

-.053 (.038)

.009 (.015)

Education: undergrad
(ref: grad/professional)

-.003 (.014)

.611 (1.215)

-.073 (.039)

-.017 (.016)

Education: high school

.012 (.017)

-1.071 (1.504)

-.067 (.047)

-.008 (.019)

NB. Each beta coefficient represents the difference between the average psychosocial response score for one level
of a predictor variable (e.g. false positive) compared to the average psychosocial response score for the reference
level of this predictor variable (e.g. screen negative); Betas are unstandardized ap=0.02
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Table 4: Qualitative themes and illustrative statements
Theme

Illustrative Statement

Mothers experience distress in the early days
The news is distressing

Just as you think everything is going so perfectly, you hear this… it is so scary;
you always think it happens to other people... (205)
I just shut down. I didn’t hear anything. She kept talking and I could tell she was
trying to calm me down, but I couldn’t hear anything she was saying. (015)
Well, I guess it kind of blew me out of the water…we signed the form in the
hospital… but didn’t know anything really about it, so forgot about it. So, when
the call came it knocked me on my butt... (050)

The news triggers symptom
monitoring

All I kept saying was ‘she’s got cystic fibrosis. That’s why...’ She was really
congested… I said, ‘oh my god, this is why she’s this. This is why this happened.
This is why she keeps throwing up when she eats.(015)
No, we just spent the two days looking up symptoms, trying to find reasons that
would explain... his behaviour because he was eating a lot.... had raspy breath.
So, I thought, oh my god, those are symptoms. We licked him. And then, I
swaddled him up and made him sweat some and licked him more… (052)
But you worry… you start to think of every little cough… she tends to drink a lot
of milk, chugs it and then spurts it all up and, you know, is that her drowning in
mucus cause she can’t drink it properly? Your brain just goes. (234)

The news leads to fearing a
life of chronic illness

But you know, my husband was sitting there in the waiting room, nervous and,
and looking at all these other poor children that are there for different reasons,
you know, are really, really sick and, and you start to really think about, this
could be my reality (173)
As soon as I got there it was even more stressful because I was, like, ‘oh my god,
I’m going to be coming here for the rest of my life…. it was really stressful… I
walked in there and I’m seeing other kids with, like... I don’t know what you call
those long stick things with, like, the drippies on them. And, I’m, like, ‘oh god,
I’m going to... that’s going to be my kid’ (017)
Really it was just fear, but it was fear for different people as well. Like, it wasn’t
just a fear for her. It was a fear for my older son and if she suddenly had a
condition that required a lot of specialists and doctor’s appointments, what did
that mean for him and our family? (141)

The system response helps to mitigate the distress that is experienced
It was quick and prescribed

Was great that we didn’t have to wait because…waiting like 2 or 3 weeks for an
appointment... You would have just made yourself sick with worry…48 hours is
long enough… if you had to wait like 2 weeks, then you know, you really get
your anxiety level up... [173]
So I was thrilled with that approach…...to have her just tell us, “show up at this
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time”... we didn’t have to do anything. So that eliminated a whole other set of
questions in what do we do now and who do I call? And, we didn’t have to do
any of that.(129)
Communication was effective
and
sensitive
from
notification to confirmation

She had a really, really positive outlook. And, she was really calm. And, you
know, I don’t... it wouldn’t have made it any worse or better hearing it from my
family doctor or something, or somebody that I knew... You know, the way she
presented the information I think made a huge difference even though I didn’t...
I’ve never spoken to her before. (153)
You could tell that she just knew what she was doing, very routine. She was
comfortable with babies. Like, she was excited. She was talking to our son. Like,
we hadn’t even started talking to our kid. And, it was just a very, like, upbeat
feeling. And, she was, like, “yeah, stay in here as long as you need to” and, like,
just very warm...and comfortable.” (035)
And, it was certainly my experience that everybody was sensitive... I felt
completely supported. And, I felt like for all I knew [she] could have been there
only for me; and that’s the way she made you feel. Like, “I’m just here for you
and it doesn’t matter; anybody can walk into my office right now. It doesn’t
matter. I’m talking to you. And, I think she was great at that. And, I think if
your other folks are making a... are like her, I don’t think you have a problem.
And, I mean, doctors or whoever making that call, as long as parents feel
supported and that you care and it’s not a... this is not routine. It may be routine
to you; it’s not routine to me. That’s the only thing. (141)

The role of early information
about newborn screening
outcomes is unresolved

You know, if my OB would have sat down with me and spoken to me for five,
ten minutes about what the results would be and, you know, potential results and
what would happen, what the steps would be if this or that happened; yes, the
pregnant woman freaks out, but it’s almost... it’s better to be kind of forewarned I
think. It gives you time to think about it. I don’t know. Instead of just somebody
coming in and, you know, doing the prick test and then two weeks later you get a
phone call, ta da! (153)
And, I’ve thought a lot about this since. I’m not so sure I would have had it any
other way. That’s kind of the problem because you kind of forget about it. But, if
nothing was wrong, so say with the second child, I’m not so sure I’d want to be
thinking about, you know, a phone call that may come. Of course I will now
because I’ve gone through it, but I’m not so sure what the right answers are. At
first I thought it would have been nice to be reminded when we left the hospital
that those... that screening was being completed, but now that I’ve sat and thought
about it I’m not so sure I would have wanted to know that either. So, I would say
we were completely shocked. I guess part of the problem too is when we signed
that form we didn’t really know what was being tested either. And, you know,
we could have looked it up for sure and I’ve since looked it up, but I had no idea
what we were even... was the potential to come up. (050)
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